Showing 81 - 100 results of 111 for search '(functional OR function) data analysis (fda)', query time: 0.10s Refine Results
  1. 81
  2. 82

    Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy by Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang

    Published 2025-06-01
    “…We also examined TMA and thrombotic thrombocytopenic purpura (TTP) risks using patient biochemical data from a local hospital and explored underlying biological mechanisms through animal models and pan‐cancer analysis. …”
    Get full text
    Article
  3. 83

    Next-Generation Cancer Treatment: Photoimmunotherapy’s Promise for Unresectable Head and Neck Cancers by Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher

    Published 2025-05-01
    “…Traditional oncological therapies have contributed to reducing the global cancer burden; however, they have not achieved complete eradication, nor have they effectively prevented relapses, minimized toxicity, or preserved immune function. Recent advances, particularly the introduction of immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have markedly improved clinical outcomes and overall survival in certain cancer subtypes. …”
    Get full text
    Article
  4. 84
  5. 85
  6. 86
  7. 87

    Exploring the heterodimer MDM2/MDM4 interaction region uncovers high-affinity peptides for therapeutic p53-reactivation by Marika Attili, Marika Attili, Sonia Valentini, Sonia Valentini, Maria Pesavento, Maria Pesavento, Marco Ballarotto, Viviana Scognamiglio, Alfredo Pontecorvi, Antonio Macchiarulo, Fulvio Saccoccia, Fabiola Moretti

    Published 2025-05-01
    “…IntroductionIn the era of targeted therapies, molecules for the reactivation of the oncosuppressor p53 in human cancer have not yet reached FDA or EMA approval. Recently, the interaction region of the MDM2/MDM4 heterodimer, the most efficient inhibitor of p53 levels and function, has been successfully targeted. …”
    Get full text
    Article
  8. 88
  9. 89
  10. 90

    Prospective Evaluation of Rate of Hindfoot/Ankle Fusion with Augment Injectable Bone Graft by Jacob Priester MD, Christopher D. Kreulen MD, Phillip J. Shaheen MD, Eric Giza MD, Samuel Simister MD

    Published 2024-12-01
    “…The patients received AIBG and were excluded if any other graft material was used. Demographic data and patient reported outcomes were collected preoperatively and at follow-up visits including Visual Analog Pain Scale (VAS), Foot Function Index (FFI), Foot and Ankle Ability Measure (FAAM) Sports Subscale, and Veterans Rand 12 (VR-12) physical and mental subscores. …”
    Get full text
    Article
  11. 91

    Comparison of new secondgeneration H1 receptor blockers with some molecules; a study involving DFT, molecular docking, ADMET, biological target and activity by Velid Unsal, Erkan Oner, Reşit Yıldız, Başak Doğru Mert

    Published 2025-01-01
    “…In this study, pharmacological activities of FDA-approved second generation H1 antihistamines (Levocetirizine, desloratadine and fexofenadine) and molecules such as CAPE, Melatonin, Curcumin, Vitamin C, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiles, density functional theory (DFT), molecular docking, biological targets and activities were compared by calculating. …”
    Get full text
    Article
  12. 92
  13. 93
  14. 94

    Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias by Venkata K. Yellepeddi, Mohamed Ismail, T. Jared Bunch, Thomas F. Deering, Richard Holubkov, Robert Kennedy, Suneet Mittal, Marco Perez, Jonathan P. Piccini, Parash Pokharel, Salvatore Savona, Nishant Verma, Benjamin Steinberg, Kevin Watt

    Published 2025-04-01
    “…This study evaluates the population pharmacokinetics (PK) and pharmacodynamics (PD) of sotalol using data from the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry, which includes patients with atrial arrhythmias undergoing IV sotalol loading. …”
    Get full text
    Article
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100